Clinical Approach to Premenstrual Symptoms

Comprehensive Practical Framework

1
Symptom Overview
Overview
2
Pathophysiology
Mechanism
3
History Taking
History
4
Physical Examination
Examination
5
Differential Diagnosis
Differential
6
Investigations
Workup
7
Clinical Decision-Making
Algorithm
8
Pearls and Pitfalls
Summary

1. Symptom Overview

Understanding the clinical significance and classification of premenstrual symptoms

Premenstrual symptoms affect up to 90% of reproductive-age women, with approximately 20-40% experiencing symptoms significant enough to impact daily functioning. Premenstrual syndrome (PMS) affects 20-30% of women, while the more severe premenstrual dysphoric disorder (PMDD) affects 3-8% of menstruating women. These symptoms account for significant healthcare utilization, work absenteeism, and reduced quality of life, with estimated annual costs exceeding $5 billion in the United States alone.

Definition

Premenstrual symptoms are a constellation of physical, emotional, and behavioral changes that occur cyclically during the luteal phase of the menstrual cycle (typically 1-2 weeks before menstruation) and resolve within a few days of menstrual onset. The hallmark feature is the cyclical timing — symptoms must be absent during the follicular phase and early to mid-luteal phase to be classified as premenstrual.

Key Epidemiology

Mild premenstrual symptoms: Up to 90% of menstruating women
Premenstrual syndrome (PMS): 20-30% of menstruating women
Premenstrual dysphoric disorder (PMDD): 3-8% of menstruating women
Peak prevalence: Late 20s to mid-30s
Impact: Up to 15% of women with PMDD report suicidal ideation

Classification by Severity

Category	Prevalence	Symptom Characteristics	Functional Impact
Mild Premenstrual Symptoms	Up to 90%	Awareness of symptoms without distress; mild physical or mood changes	No significant interference with daily activities or relationships
Premenstrual Syndrome (PMS)	20-30%	Moderate physical and/or psychological symptoms causing distress	Some interference with work, social activities, or relationships
Premenstrual Dysphoric Disorder (PMDD)	3-8%	Severe affective symptoms (marked mood lability, irritability, depression, anxiety)	Significant impairment in occupational, social, or interpersonal functioning

Classification by Symptom Domain

Affective Symptoms

Mood-related manifestations:

Irritability and anger
Depressed mood and tearfulness
Anxiety and tension
Mood lability and emotional sensitivity
Decreased interest in activities
Difficulty concentrating

Physical Symptoms

Somatic manifestations:

Breast tenderness and swelling (mastalgia)
Abdominal bloating and distension
Headaches (often migrainous)
Peripheral edema
Weight gain (fluid retention)
Muscle and joint pain

Behavioral Symptoms

Behavioral manifestations:

Fatigue and low energy
Sleep disturbances (hypersomnia or insomnia)
Appetite changes and food cravings
Decreased libido
Social withdrawal
Impaired concentration

Classification by Timing Pattern

Pattern	Description	Clinical Significance
Classic Premenstrual	Symptoms begin 7-14 days before menses and resolve within 4 days of menstrual onset	Most common pattern; classic PMS/PMDD presentation
Late Luteal Only	Symptoms begin only 3-7 days before menses	May be milder; responsive to shorter treatment courses
Premenstrual Exacerbation	Underlying condition (depression, anxiety, migraine) worsens premenstrually but symptoms persist throughout cycle	Critical to distinguish from true PMS/PMDD; requires treatment of underlying condition
Perimenstrual	Symptoms span from late luteal through early menstruation	Common pattern; may benefit from extended treatment timing

Diagnostic Criteria for Premenstrual Dysphoric Disorder (DSM-5)

Criterion A: In the majority of menstrual cycles, at least 5 symptoms must be present in the final week before menses, improve within a few days after onset of menses, and become minimal or absent in the week post-menses.

Criterion B: At least ONE of the following must be present:

Marked affective lability (mood swings, sudden sadness, increased sensitivity to rejection)
Marked irritability, anger, or increased interpersonal conflicts
Marked depressed mood, hopelessness, or self-deprecating thoughts
Marked anxiety, tension, or feeling “keyed up” or “on edge”

Criterion C: Additionally, one or more of the following (total of 5+ symptoms with Criterion B):

Decreased interest in usual activities
Difficulty concentrating
Fatigue, lethargy, or marked lack of energy
Marked change in appetite, overeating, or food cravings
Hypersomnia or insomnia
Feeling overwhelmed or out of control
Physical symptoms (breast tenderness, bloating, joint/muscle pain, weight gain)

Criterion D: Symptoms cause clinically significant distress or interference with functioning.

Criterion E: Not merely an exacerbation of another disorder.

Criterion F: Confirmed by prospective daily ratings for at least 2 symptomatic cycles.

Key Concept — The Diagnostic Triad: True premenstrual symptoms must demonstrate:

Cyclicity: Symptoms occur in the luteal phase and resolve with menstruation
Symptom-Free Interval: At least one week of the cycle (follicular phase) must be symptom-free
Functional Impairment: Symptoms cause distress or interfere with daily functioning

Without a symptom-free interval, consider premenstrual exacerbation of an underlying mood or medical disorder rather than primary PMS/PMDD.

Impact on Quality of Life

Domain	PMS Impact	PMDD Impact
Occupational	Reduced productivity, occasional absenteeism	Significant absenteeism, job loss risk, disability
Interpersonal	Increased conflicts, irritability with family	Relationship breakdowns, social isolation, domestic conflicts
Academic	Difficulty concentrating, reduced performance	School avoidance, examination failures
Mental Health	Frustration, mild distress	Suicidal ideation (15%), increased psychiatric comorbidity

2. Pathophysiology and Mechanisms

Understanding the underlying mechanisms of premenstrual symptoms

Premenstrual symptoms arise from a complex interplay between ovarian steroid hormones and central neurotransmitter systems. Importantly, women with PMS/PMDD do not have abnormal hormone levels — rather, they exhibit an abnormal sensitivity of the central nervous system to normal hormonal fluctuations during the luteal phase. This “abnormal response to normal hormones” paradigm is fundamental to understanding why symptoms occur and how treatments work.

The Core Paradigm

Women with PMS and PMDD have normal ovarian hormone levels but demonstrate abnormal central nervous system sensitivity to the physiological hormonal changes of the menstrual cycle. The symptoms are triggered by hormone fluctuations (particularly progesterone and its metabolites), not by hormone excess or deficiency.

The Menstrual Cycle: Hormonal Context

Phase	Days (28-day cycle)	Hormonal Environment	Symptom Status
Menstrual Phase	Days 1-5	Low estrogen and progesterone; hormone withdrawal	Symptoms resolve within first few days
Follicular Phase	Days 6-13	Rising estrogen; low progesterone	Symptom-free interval (required for diagnosis)
Ovulation	Day 14	Estrogen peak; luteinizing hormone surge	Typically symptom-free
Early Luteal Phase	Days 15-21	Rising progesterone; moderate estrogen	Symptoms may begin late in this phase
Late Luteal Phase	Days 22-28	Declining progesterone and estrogen	Peak symptom severity; the “premenstrual window”

Key Hormonal and Neurobiological Mechanisms

Progesterone and Allopregnanolone

Central role in symptom generation:

Progesterone is metabolized to allopregnanolone, a potent neuroactive steroid
Allopregnanolone is a positive allosteric modulator of GABA-A receptors
In most women, allopregnanolone has anxiolytic and calming effects
In PMS/PMDD, there may be paradoxical responses or altered receptor sensitivity
Rapid fluctuations in allopregnanolone may trigger symptoms

Serotonergic System

Critical for affective symptoms:

Estrogen and progesterone modulate serotonin synthesis and receptor density
Luteal phase is associated with decreased serotonin activity
Women with PMDD show blunted serotonergic responses
Explains rapid efficacy of selective serotonin reuptake inhibitors (SSRIs)
Tryptophan depletion studies worsen symptoms in vulnerable women

Neurotransmitter Systems Involved

System	Hormonal Modulation	Effect in Luteal Phase	Clinical Manifestation
Serotonin (5-HT)	Estrogen increases 5-HT synthesis; progesterone decreases receptor sensitivity	Reduced serotonergic tone	Depressed mood, irritability, carbohydrate cravings, impulsivity
GABA	Allopregnanolone potentiates GABA-A receptors	Paradoxical anxiety in susceptible women; altered receptor subunit expression	Anxiety, tension, mood lability
Dopamine	Estrogen enhances dopaminergic activity	Reduced dopamine tone as estrogen declines	Anhedonia, fatigue, decreased motivation
Norepinephrine	Modulated by both estrogen and progesterone	Dysregulated noradrenergic activity	Anxiety, hypervigilance, concentration difficulties
Beta-Endorphin	Levels parallel progesterone changes	Declining endorphins in late luteal phase	Pain sensitivity, dysphoria

Pathophysiology of Specific Symptom Domains

Mood Symptoms (Irritability, Depression, Anxiety)

Mechanism	Explanation	Treatment Implication
Serotonin deficiency	Declining estrogen reduces serotonin synthesis and receptor binding	SSRIs are first-line treatment; work rapidly (within days) in PMDD
Allopregnanolone sensitivity	Abnormal GABA-A receptor response to progesterone metabolites	Ovulation suppression eliminates progesterone fluctuations
HPA axis dysregulation	Blunted cortisol response to stress in luteal phase	Stress reduction strategies may help
Neuroinflammation	Elevated inflammatory markers in some women with PMDD	Anti-inflammatory approaches under investigation

Bloating and Fluid Retention

Mechanism	Explanation	Treatment Implication
Estrogen effect on fluid balance	Estrogen promotes sodium and water retention via renal mechanisms	Spironolactone (aldosterone antagonist) may help
Progesterone and aldosterone	Progesterone competes with aldosterone at mineralocorticoid receptors, triggering compensatory aldosterone secretion	Drospirenone-containing oral contraceptives have anti-mineralocorticoid effects
Altered gastrointestinal motility	Progesterone slows gut motility, contributing to bloating sensation	Dietary modifications, avoiding gas-producing foods
Visceral hypersensitivity	Heightened perception of abdominal distension without actual volume increase	May not respond to diuretics; behavioral approaches may help

Breast Pain (Mastalgia)

Mechanism	Explanation	Treatment Implication
Estrogen-induced ductal proliferation	Estrogen stimulates epithelial cell proliferation in breast ducts	Reducing estrogen exposure may help
Progesterone-induced lobular changes	Progesterone causes lobular-alveolar development and glandular secretion	Symptoms correlate with luteal phase progesterone
Increased breast tissue water content	Fluid retention within breast tissue causes engorgement	Evening primrose oil (gamma-linolenic acid) may modulate prostaglandins
Prolactin effects	Elevated prolactin may contribute in some women	Rarely, dopamine agonists considered

Genetic and Environmental Modulators

Genetic Factors

Heritability: Twin studies suggest 30-80% heritability for PMS/PMDD
ESC/E(Z) gene complex: Altered expression in women with PMDD affects cellular response to sex steroids
Serotonin transporter polymorphisms: May influence SSRI response
GABA-A receptor subunit variants: May explain differential sensitivity to allopregnanolone

Environmental and Lifestyle Factors

History of trauma: Increases risk of PMDD; shared vulnerability with PTSD
Chronic stress: HPA axis dysregulation may worsen symptoms
Smoking: Associated with increased PMS severity
Obesity: Adipose tissue affects hormone metabolism
Diet: High sodium, caffeine, and simple carbohydrate intake may worsen symptoms

Often Overlooked Mechanism

SSRIs work differently in PMDD than in major depression. In major depressive disorder, SSRIs require 4-6 weeks for therapeutic effect due to receptor downregulation. In PMDD, SSRIs work within 24-48 hours, suggesting a different mechanism — likely rapid enhancement of allopregnanolone synthesis from progesterone, which then modulates GABA-A receptors. This allows for intermittent dosing (luteal phase only) in PMDD, which is not possible in major depression.

Integrated Pathophysiology Model

The Cascade of Premenstrual Symptoms:

Ovulation occurs → Corpus luteum forms → Progesterone rises
Progesterone metabolized → Allopregnanolone production increases
In susceptible women: Abnormal CNS response to allopregnanolone and serotonin/GABA changes
Late luteal phase: Declining hormones trigger symptom cascade
Menstruation: Hormone withdrawal complete → Symptoms resolve
Follicular phase: Stable low progesterone → Symptom-free interval

3. History Taking

A comprehensive approach to eliciting the premenstrual symptom history

Red Flags — Require Urgent Evaluation

Suicidal ideation or self-harm thoughts — Psychiatric emergency; up to 15% of PMDD patients
Symptoms persist throughout the cycle — Not true PMS; consider underlying mood disorder
New onset after age 40 — Consider perimenopause, thyroid disease, or organic pathology

Severe unilateral breast pain or mass — Exclude breast pathology
Significant abdominal distension with pain — Exclude ovarian pathology, ascites
Rapid weight gain (>5 kg) with edema — Exclude cardiac, renal, or hepatic causes

Systematic History: The “CYCLES” Approach

Use the mnemonic “CYCLES” to ensure comprehensive history taking for premenstrual symptoms:

C — Character and Catalog of Symptoms: What symptoms do you experience? (mood, physical, behavioral) How severe are they on a scale of 1-10?
Y — Your Menstrual Cycle Timing: When do symptoms start relative to your period? When do they resolve? Do you have a symptom-free week?
C — Consequences and Impact: How do symptoms affect your work, relationships, and daily activities? Any missed days of work or school?
L — Length of Time and Life Stage: How long have you had these symptoms? Did they start after a hormonal event (menarche, pregnancy, starting/stopping contraception)?
E — Exacerbating and Easing Factors: What makes symptoms worse (stress, diet, sleep)? What has helped (medications, lifestyle changes)?
S — Safety and Psychiatric Screening: Any thoughts of self-harm? History of depression, anxiety, or trauma? Family history of mood disorders or PMDD?

Establishing Cyclicity: The Critical Diagnostic Question

The Most Important Question

“Is there a time during your menstrual cycle when you feel completely well — like your normal self?”

A positive answer (typically during the follicular phase, days 6-12) supports true PMS/PMDD. If symptoms are present throughout the cycle with premenstrual worsening, this suggests premenstrual exacerbation of an underlying condition rather than primary PMS/PMDD.

Characterizing Symptoms by Domain

Symptom Domain	Specific Symptoms to Ask About	Key Questions
Affective (Mood)	Irritability, anger outbursts, sadness, tearfulness, anxiety, tension, mood swings, sensitivity to rejection	“Do you find yourself more easily frustrated or snapping at people before your period?” “Do you feel more anxious or on edge?”
Cognitive	Difficulty concentrating, forgetfulness, feeling overwhelmed, indecisiveness	“Do you notice it’s harder to focus or remember things in the week before your period?”
Physical — Breast	Breast tenderness, swelling, heaviness, pain with movement or touch	“Do your breasts become sore or swollen? Is it both breasts equally? Does it resolve once your period starts?”
Physical — Bloating	Abdominal distension, feeling of fullness, tight clothing, visible swelling	“Do you feel bloated before your period? Do you need to wear looser clothing? Is there actual visible swelling or just a sensation?”
Physical — Other	Headaches, joint pain, muscle aches, fatigue, weight gain, acne flares	“Do you get headaches before your period? Any joint or muscle pain? How is your energy level?”
Behavioral	Food cravings, overeating, sleep changes, social withdrawal, decreased libido	“Do you notice changes in appetite or cravings? How is your sleep? Do you tend to withdraw from activities?”

Targeted Questions by Suspected Diagnosis

Suspected Diagnosis	Key Features	Ask This Question
Premenstrual Dysphoric Disorder (PMDD)	Severe mood symptoms, significant functional impairment, symptom-free follicular phase	“Do your mood symptoms cause problems at work or in your relationships? Have you ever missed work or avoided social situations because of how you felt premenstrually?”
Premenstrual Exacerbation of Depression	Baseline depressive symptoms present throughout cycle, worsen premenstrually	“Even during your best week, do you still have some degree of low mood, low energy, or difficulty enjoying things?”
Premenstrual Exacerbation of Anxiety	Baseline anxiety present, intensifies premenstrually	“Do you experience anxiety or worry throughout your cycle, just more so before your period?”
Menstrual Migraine	Migraine occurring within 2 days before to 3 days after menstruation onset	“Do your headaches specifically occur right around when your period starts? Are they one-sided, throbbing, with nausea or light sensitivity?”
Thyroid Dysfunction	Fatigue, mood changes, weight changes, menstrual irregularity	“Have you noticed any changes in your weight, hair, skin, or tolerance to temperature? Any neck swelling?”
Perimenopause	New or worsening symptoms in 40s, irregular cycles, vasomotor symptoms	“Have your periods become irregular? Any hot flashes or night sweats? When was your last period?”

Prospective Symptom Tracking: The Diagnostic Gold Standard

Daily Symptom Diary

Retrospective recall of symptoms is unreliable. For definitive diagnosis of PMS or PMDD, patients should complete a prospective daily symptom diary for at least 2 consecutive menstrual cycles. Validated tools include:

Daily Record of Severity of Problems (DRSP): 24-item scale; gold standard for research and clinical diagnosis
Premenstrual Symptoms Screening Tool (PSST): Retrospective screening tool; useful for initial assessment
Calendar of Premenstrual Experiences (COPE): Daily tracking of 22 symptoms
Smartphone apps: Many menstrual tracking apps now include mood and symptom tracking features

Instruct patients to rate symptom severity daily (0 = none, 1 = mild, 2 = moderate, 3 = severe) and mark menstruation days.

Gynecologic and Reproductive History

Menstrual History

Age of menarche: Earlier menarche may increase PMS risk
Cycle regularity: Regular cycles needed to establish luteal timing
Cycle length: Affects timing of luteal phase treatment
Duration and flow: Heavy menstrual bleeding may worsen fatigue
Dysmenorrhea: Often coexists with PMS
Last menstrual period: Confirm not pregnant; establish cycle phase

Reproductive and Contraceptive History

Pregnancies: Some women report symptom changes after pregnancy
Postpartum depression history: Risk factor for PMDD
Current contraception: Hormonal methods may help or worsen symptoms
Previous contraceptive trials: Response to prior hormonal therapy
Fertility goals: Affects treatment options (SSRIs, hormonal therapy)
Perimenopause symptoms: If age-appropriate

Medication and Substance History

Medications That May Affect Symptoms

Hormonal contraceptives: May improve or worsen PMS; continuous regimens may help by eliminating hormone fluctuations
Antidepressants: SSRIs may already be treating underlying condition
Hormone replacement therapy: Progesterone component may trigger symptoms
Corticosteroids: Can cause mood changes, fluid retention
NSAIDs: Patient may already be self-treating
Diuretics: May mask fluid retention symptoms

Substances and Lifestyle Factors

Caffeine: May worsen anxiety, breast tenderness, and sleep
Alcohol: Depressant effects may worsen mood; often increased premenstrually
Smoking: Associated with increased PMS severity
Recreational drugs: May mask or exacerbate symptoms
Supplements: Calcium, vitamin B6, evening primrose oil use
Dietary patterns: High salt, sugar, processed food intake

Psychiatric and Family History

History Element	Relevance	Key Questions
Personal psychiatric history	Depression and anxiety are common comorbidities; must distinguish from premenstrual exacerbation	“Have you ever been diagnosed with depression, anxiety, bipolar disorder, or another mental health condition?”
History of trauma	Trauma history, especially childhood abuse, increases PMDD risk	“Have you experienced any traumatic events in your life that still affect you?”
Family history of PMS/PMDD	Strong genetic component; 30-80% heritability	“Did your mother or sisters have significant problems with PMS?”
Family history of mood disorders	Shared genetic vulnerability for mood dysregulation	“Is there any family history of depression, anxiety, or bipolar disorder?”
Current safety assessment	Suicidal ideation occurs in up to 15% of PMDD patients	“When your symptoms are at their worst, do you ever have thoughts of harming yourself or not wanting to be alive?”

Social and Occupational History

Occupational Impact

Days missed from work due to symptoms
Reduced productivity or performance issues
Conflicts with colleagues premenstrually
Career limitations or job changes
Shift work affecting sleep patterns

Relationship and Social Impact

Partner relationship strain or conflict
Effects on parenting and children
Social withdrawal or isolation
Avoidance of activities during luteal phase
Support system availability

4. Physical Examination

A systematic approach for patients presenting with premenstrual symptoms

Key Principle: The physical examination in PMS/PMDD is primarily to exclude other conditions that may mimic or contribute to premenstrual symptoms. In true PMS/PMDD, the physical examination is typically normal or shows only minor, non-specific findings. A thorough examination is essential to identify treatable organic causes and reassure patients.

General Inspection

Appearance and demeanor: Assess for signs of depression (psychomotor retardation, poor eye contact, flat affect) or anxiety (restlessness, hypervigilance)
Body habitus: Note obesity (BMI >30), which is associated with increased PMS severity and altered hormone metabolism
Visible edema: Facial puffiness, periorbital edema, ankle swelling — may support fluid retention complaints
Skin: Acne flares (common premenstrually), hirsutism (consider polycystic ovary syndrome), pallor (anemia from heavy menstrual bleeding)
Signs of distress: Tearfulness, agitation, or flat affect during consultation

Vital Signs

Vital Sign	What to Look For	Clinical Significance
Blood Pressure	Hypertension, orthostatic changes	Exclude hypertension as cause of headaches; orthostatic hypotension may suggest dehydration or autonomic dysfunction
Heart Rate	Tachycardia, irregularity	Tachycardia may indicate anxiety, thyroid disease, or anemia; palpitations are a common PMS complaint
Weight	Compare to previous visits; calculate BMI	Document baseline for monitoring; weight fluctuation of 1-3 kg premenstrually is common due to fluid retention
Temperature	Fever	Fever suggests infection rather than PMS; basal body temperature rises 0.3-0.5°C in luteal phase (normal finding)

Thyroid Examination

Why Thyroid Examination Matters

Thyroid dysfunction (both hypothyroidism and hyperthyroidism) can mimic PMS symptoms including fatigue, mood changes, weight fluctuations, and menstrual irregularity. Always examine the thyroid in patients presenting with premenstrual symptoms, especially if symptoms are new or atypical.

Inspection: Visible goiter, asymmetry, or masses
Palpation: Thyroid size, nodules, tenderness (subacute thyroiditis)
Associated signs of hypothyroidism: Dry skin, coarse hair, periorbital edema, delayed relaxation of deep tendon reflexes, bradycardia
Associated signs of hyperthyroidism: Tremor, lid lag, exophthalmos, tachycardia, hyperreflexia, warm moist skin

Breast Examination

Breast tenderness (mastalgia) is one of the most common premenstrual physical symptoms. The examination serves to exclude pathology and characterize the nature of breast symptoms.

Inspection

Symmetry of breasts (mild asymmetric swelling premenstrually is common)
Skin changes: dimpling, peau d’orange, erythema, ulceration (all concerning for malignancy)
Nipple changes: inversion, deviation, discharge, eczematous changes (Paget’s disease)

Palpation

Cyclical bilateral tenderness: Consistent with hormonal mastalgia; typically upper outer quadrants
Nodularity: Diffuse nodularity (fibrocystic changes) is common and usually benign
Discrete masses: Any distinct mass requires further evaluation regardless of cycle timing
Axillary lymph nodes: Palpate for lymphadenopathy

Finding	Characteristics	Clinical Significance
Cyclical bilateral tenderness	Diffuse, bilateral, worse in upper outer quadrants, resolves with menses	Consistent with hormonal (premenstrual) mastalgia — reassuring
Non-cyclical focal pain	Unilateral, localized, no clear relationship to cycle	May represent musculoskeletal cause (Tietze syndrome) or requires imaging to exclude pathology
Discrete mass	Distinct lump, mobile or fixed, any size	Requires breast imaging regardless of age or cycle timing
Nipple discharge	Spontaneous, unilateral, bloody or clear	Requires further investigation; bilateral milky discharge suggests hyperprolactinemia

Abdominal Examination

Bloating is a cardinal premenstrual symptom. The abdominal examination helps differentiate subjective bloating from objective distension and excludes organic pathology.

Inspection

Distension: Note whether abdomen appears distended; ask patient to compare to baseline
Visible masses: Large ovarian cysts or uterine fibroids may be visible
Striae, scars: Prior surgeries, signs of rapid weight change

Palpation

Tenderness: Generalized mild tenderness may occur; localized or severe tenderness suggests other pathology
Masses: Palpate for ovarian masses, uterine enlargement, or other abdominal masses
Hepatomegaly: May indicate hepatic causes of edema or hormonal dysfunction
Ascites: Shifting dullness, fluid wave — excludes simple premenstrual bloating

Percussion

Tympany: Suggests gaseous distension (common with premenstrual bloating due to slowed gut motility)
Dullness: May indicate fluid (ascites) or solid mass
Shifting dullness: Suggests free peritoneal fluid — not consistent with simple PMS

Pelvic Examination

When to Perform Pelvic Examination

A pelvic examination is not routinely required for diagnosis of PMS/PMDD if history is classic and there are no red flags. However, consider pelvic examination if:

Significant pelvic pain or dysmenorrhea is present
Abnormal uterine bleeding accompanies symptoms
Abdominal or pelvic mass is suspected
Symptoms suggest endometriosis or adenomyosis
Patient is due for routine cervical screening

External Genitalia

Usually normal in PMS/PMDD
Note any vulvar lesions, discharge, or signs of infection

Speculum Examination

Cervix: Note any lesions, discharge, cervical motion tenderness
Vaginal discharge: Exclude vaginitis as cause of discomfort

Bimanual Examination

Uterine size: Enlarged uterus suggests fibroids or adenomyosis
Uterine tenderness: Tenderness may suggest adenomyosis
Adnexal masses: Ovarian cysts or masses require imaging
Adnexal tenderness: May suggest endometriosis or pelvic inflammatory disease
Uterosacral nodularity: Suggestive of deep endometriosis

Extremities and Edema Assessment

Finding	Characteristics	Clinical Significance
Mild peripheral edema	Bilateral ankle swelling, pitting, improves overnight, cyclical pattern	Consistent with premenstrual fluid retention — common and benign
Significant pitting edema	Marked swelling, slow to resolve, extends above ankles	Consider cardiac, renal, or hepatic causes; may need further investigation
Unilateral leg swelling	Asymmetric, may be warm or tender	Consider deep vein thrombosis — not PMS; requires urgent evaluation
Hand and finger swelling	Rings feel tight, difficulty making fist	Common premenstrual complaint; exclude inflammatory arthritis if persistent

Focused Neurological Examination

If headache is a prominent symptom, a focused neurological examination is warranted.

Mental status: Concentration, memory (often subjectively impaired premenstrually)
Cranial nerves: Visual fields, pupillary responses, fundoscopy (papilledema)
Motor and sensory: Any focal deficits require urgent evaluation
Reflexes: Hyperreflexia may suggest thyroid disease

Mental Status Assessment

Domain	What to Observe	Clinical Significance
Appearance	Grooming, hygiene, appropriateness of dress	Marked decline may suggest severe depression
Behavior	Psychomotor agitation or retardation, eye contact	Agitation common in PMDD; retardation suggests depression
Mood and Affect	Described mood, observed affect, congruence, reactivity	Irritable, anxious, or depressed mood typical; note if affect is flat or labile
Thought Content	Suicidal ideation, hopelessness, worthlessness	Must be assessed in all PMDD patients; 15% report suicidal ideation
Cognition	Attention, concentration (may use brief screening if concerned)	Subjective cognitive complaints are common; marked impairment needs further evaluation

Expected Findings by Condition

Condition	General Appearance	Key Physical Findings	What Distinguishes It
PMS/PMDD	Usually normal; may appear distressed during luteal phase	Typically normal; may have mild breast tenderness, slight peripheral edema	Normal examination is the rule; diagnosis is clinical based on history
Hypothyroidism	Fatigue, dry skin, weight gain	Goiter, bradycardia, delayed reflexes, periorbital edema, dry skin	Symptoms present throughout cycle, not just premenstrually
Hyperthyroidism	Anxious, restless, weight loss despite appetite	Tachycardia, tremor, warm moist skin, lid lag, goiter	Constant symptoms; menstrual irregularity common
Polycystic Ovary Syndrome	May have obesity, acne	Hirsutism, acne, acanthosis nigricans, obesity	Oligomenorrhea or amenorrhea; symptoms not cyclical
Endometriosis	May appear in pain	Uterosacral nodularity, fixed retroverted uterus, adnexal tenderness	Significant dysmenorrhea, dyspareunia; pelvic findings on examination
Major Depressive Disorder	Psychomotor retardation, poor grooming	Flat affect, poor eye contact, slowed movements	Symptoms persistent throughout cycle (no symptom-free interval)

Important Teaching Point

Normal examination is expected in PMS/PMDD! Unlike many medical conditions, premenstrual syndrome and premenstrual dysphoric disorder are diagnosed primarily on history and prospective symptom tracking. The physical examination serves to:

Exclude organic conditions that mimic PMS (thyroid disease, anemia, pelvic pathology)
Identify any findings that warrant further investigation
Reassure the patient that there is no serious underlying pathology
Build rapport and demonstrate that symptoms are being taken seriously

A normal examination should not lead to dismissal of symptoms. PMS and PMDD are real conditions with neurobiological underpinnings, and a normal physical examination is entirely consistent with the diagnosis.

5. Differential Diagnosis

Systematic approach organized by probability and clinical features

When a patient presents with symptoms they attribute to their menstrual cycle, the clinician must consider whether these represent true premenstrual syndrome (PMS) or premenstrual dysphoric disorder (PMDD), premenstrual exacerbation of an underlying condition, or an unrelated disorder that the patient has incorrectly linked to their cycle. The key diagnostic challenge is establishing cyclicity — true premenstrual conditions have a symptom-free interval during the follicular phase.

Step-by-Step Diagnostic Approach:

Step 1: Confirm cyclicity — Are symptoms truly limited to the luteal phase with a symptom-free follicular phase?
Step 2: Assess severity — Do symptoms cause functional impairment? (Distinguishes PMS from normal premenstrual changes)
Step 3: Screen for PMDD — Are severe affective symptoms present? (At least one of: marked mood lability, irritability, depression, or anxiety)
Step 4: Exclude mimics — Consider thyroid disease, anemia, perimenopause, and other organic causes
Step 5: Identify premenstrual exacerbation — Is there an underlying condition that worsens premenstrually?

Primary Premenstrual Conditions

Condition	Prevalence	Key Distinguishing Features	Diagnostic Requirement
Mild Premenstrual Symptoms (Normal)	Up to 90%	Awareness of symptoms without distress; no functional impairment; symptoms do not interfere with daily life	No treatment required; reassurance
Premenstrual Syndrome (PMS)	20-30%	Physical and/or mood symptoms causing distress; some functional impairment; symptom-free follicular phase	Prospective symptom diary × 2 cycles; functional impairment documented
Premenstrual Dysphoric Disorder (PMDD)	3-8%	Severe affective symptoms predominate; marked irritability, mood lability, depression, or anxiety; significant impairment	DSM-5 criteria met; prospective confirmation × 2 cycles; ≥5 symptoms including ≥1 core affective symptom
Premenstrual Exacerbation (PME)	Variable	Underlying condition present throughout cycle but worsens premenstrually; NO symptom-free week	Identify and treat underlying condition; symptoms persist (though milder) in follicular phase

Conditions Commonly Showing Premenstrual Exacerbation

Condition	Baseline Symptoms	Premenstrual Worsening Pattern	Clinical Clue
Major Depressive Disorder	Persistent low mood, anhedonia, sleep/appetite changes throughout cycle	Depression intensifies in luteal phase; may have suicidal ideation	No true symptom-free week; depressive symptoms present even at “best” time of cycle
Generalized Anxiety Disorder	Chronic worry, tension, restlessness present daily	Anxiety peaks premenstrually; panic attacks may cluster	Anxiety present throughout cycle; patient never feels “calm” even in follicular phase
Bipolar Disorder	Mood episodes throughout cycle	Depressive episodes or rapid cycling may worsen premenstrually	History of manic or hypomanic episodes; family history of bipolar disorder
Migraine	Episodic headaches at various times	Menstrual migraine: attacks within -2 to +3 days of menstruation; often more severe and treatment-resistant	Headaches also occur at other times of cycle; typical migraine features present
Irritable Bowel Syndrome	Chronic abdominal pain, altered bowel habits	Bloating, diarrhea, or constipation worsen premenstrually	Gastrointestinal symptoms present throughout cycle, not just premenstrually
Asthma	Chronic airway symptoms	Perimenstrual asthma: worsening around menstruation in 30-40% of female asthmatics	Asthma symptoms present at other times; spirometry abnormalities
Epilepsy	Seizures at various times	Catamenial epilepsy: seizure clustering around menstruation	Documented seizures; abnormal EEG; seizures occur at other times too

Medical Conditions That Mimic Premenstrual Symptoms

Probability	Condition	Overlapping Symptoms	Key Distinguishing Features
COMMON	Hypothyroidism	Fatigue, weight gain, depressed mood, constipation, edema, menstrual changes	Symptoms constant, not cyclical; cold intolerance; dry skin; elevated TSH
COMMON	Iron Deficiency Anemia	Fatigue, poor concentration, irritability, headaches	Symptoms constant; heavy menstrual bleeding history; pallor; low ferritin
COMMON	Perimenopause	Mood swings, irritability, sleep disturbance, irregular cycles, bloating	Age typically >40; irregular cycles; vasomotor symptoms (hot flashes, night sweats)
LESS COMMON	Hyperthyroidism	Anxiety, irritability, palpitations, weight changes, menstrual irregularity	Symptoms constant; weight loss despite appetite; tremor; heat intolerance; suppressed TSH
LESS COMMON	Diabetes Mellitus	Fatigue, mood changes, weight changes	Polyuria, polydipsia; symptoms not cyclical; elevated glucose
LESS COMMON	Chronic Fatigue Syndrome	Fatigue, cognitive difficulties, sleep disturbance	Post-exertional malaise; symptoms present >6 months continuously
UNCOMMON	Hyperprolactinemia	Breast tenderness, menstrual irregularity, mood changes	Galactorrhea; amenorrhea or oligomenorrhea; elevated prolactin
UNCOMMON	Addison’s Disease	Fatigue, weakness, mood changes, salt craving	Hyperpigmentation; postural hypotension; symptoms constant; low cortisol
UNCOMMON	Systemic Lupus Erythematosus	Fatigue, joint pain, mood changes	Rash, arthritis, other systemic features; positive autoantibodies

Categorical Approach to Differential Diagnosis

Endocrine Causes

Hypothyroidism

Hyperthyroidism

Hyperprolactinemia

Perimenopause

Polycystic ovary syndrome

Adrenal insufficiency

Diabetes mellitus

Psychiatric Conditions

Major depressive disorder

Generalized anxiety disorder

Panic disorder

Bipolar disorder

Persistent depressive disorder (dysthymia)

Post-traumatic stress disorder

Adjustment disorder

Gynecologic Conditions

Endometriosis

Adenomyosis

Uterine fibroids

Ovarian cysts

Primary dysmenorrhea

Chronic pelvic pain

Other Medical Conditions

Iron deficiency anemia

Chronic fatigue syndrome

Fibromyalgia

Irritable bowel syndrome

Migraine disorder

Sleep disorders

Drug-Induced Symptoms Mimicking PMS

Drug or Drug Class	Symptoms That May Mimic PMS	Mechanism	Clinical Consideration
Combined Oral Contraceptives	Mood changes, breast tenderness, bloating, headaches	Exogenous hormones; progestin effects; hormone-free interval withdrawal	Symptoms may occur during hormone-free week (withdrawal) or throughout; trial of different formulation or continuous dosing
Progestin-Only Contraceptives	Mood changes, breast tenderness, bloating, irregular bleeding	Progestin effects on CNS and fluid balance	May worsen PMS in susceptible women; consider alternative contraception
Hormone Replacement Therapy (with progestogen)	Mood changes, breast tenderness, bloating	Cyclical progestogen component triggers symptoms similar to luteal phase	Continuous combined regimens may help; consider different progestogen
Antidepressants (during initiation or withdrawal)	Mood changes, anxiety, sleep disturbance	Serotonergic effects during dose adjustment	Distinguish from PMS by timing; symptoms related to medication changes, not cycle
Corticosteroids	Mood changes (irritability, anxiety, depression), weight gain, fluid retention	Direct CNS effects; mineralocorticoid activity	Symptoms present throughout use, not cyclically
Beta-Blockers	Fatigue, depressed mood	CNS effects; reduced sympathetic activity	Symptoms constant while on medication
Benzodiazepines (withdrawal)	Anxiety, irritability, insomnia	GABA receptor downregulation	Related to medication reduction, not menstrual cycle
Stimulants (caffeine, amphetamines)	Anxiety, irritability, sleep disturbance, palpitations	Catecholamine effects	Related to use or withdrawal pattern, not cycle

Quick Reference: “If You See This, Think This”

Clinical Clue	Think This First	Next Step
Symptom-free follicular phase confirmed	True PMS or PMDD	Assess severity; if severe affective symptoms, evaluate for PMDD using DSM-5 criteria
No symptom-free week; symptoms persist throughout cycle	Premenstrual exacerbation of underlying condition	Screen for depression, anxiety, or other chronic condition; treat underlying disorder
New symptoms after age 40 with irregular cycles	Perimenopause	Check FSH (if indicated); assess for vasomotor symptoms; consider hormone therapy
Fatigue, cold intolerance, weight gain, constipation	Hypothyroidism	Check TSH; treat if abnormal
Fatigue with heavy menstrual bleeding	Iron deficiency anemia	Check complete blood count and ferritin; treat anemia and investigate bleeding
Breast tenderness with galactorrhea	Hyperprolactinemia	Check prolactin level; pituitary imaging if elevated
Suicidal ideation during luteal phase	Severe PMDD (psychiatric emergency)	Immediate safety assessment; consider urgent psychiatric referral; start SSRI
Headaches specifically at menstruation onset	Menstrual migraine	Migraine-specific treatment; consider perimenstrual prophylaxis
Mood symptoms started with hormonal contraception	Hormonal contraceptive side effect	Trial of discontinuation or alternative method; reassess after 2-3 cycles off hormones
Significant pelvic pain with dysmenorrhea and dyspareunia	Endometriosis	Pelvic examination; consider pelvic ultrasound; gynecology referral

Differentiating PMS from PMDD

Feature	Premenstrual Syndrome (PMS)	Premenstrual Dysphoric Disorder (PMDD)
Predominant symptoms	Mix of physical and mood symptoms; physical often predominate	Severe affective symptoms must be present (mood lability, irritability, depression, anxiety)
Severity	Moderate; causes distress but manageable	Severe; significantly impairs functioning
Functional impairment	Some interference with work, relationships, or activities	Marked impairment; missed work, relationship problems, social withdrawal
Suicidal ideation	Rare	Present in up to 15% of patients
Diagnostic criteria	No standardized criteria; clinical diagnosis based on symptom pattern and impact	DSM-5 criteria: ≥5 symptoms with ≥1 core affective symptom; prospective confirmation required
Treatment approach	Often responds to lifestyle modifications, supplements, or mild interventions	Usually requires pharmacotherapy (SSRIs) or hormonal suppression of ovulation

6. Diagnostic Investigations

A stepwise, cost-effective approach guided by clinical suspicion

Key Principle

PMS and PMDD are clinical diagnoses. There is no laboratory test that confirms the diagnosis. The role of investigations is to:

Exclude medical conditions that mimic premenstrual symptoms
Identify comorbid conditions requiring treatment
Establish baseline values before initiating therapy

The most important “investigation” is the prospective symptom diary, which confirms the cyclical pattern and establishes the diagnosis.

The Prospective Symptom Diary: The Cornerstone of Diagnosis

Why Prospective Tracking is Essential:

Retrospective recall of symptoms is notoriously unreliable
Up to 50% of women who believe they have PMS do not demonstrate cyclicity on prospective tracking
Prospective confirmation over 2 cycles is required for PMDD diagnosis (DSM-5 Criterion F)
Identifies the symptom-free interval (or its absence, suggesting premenstrual exacerbation)
Quantifies symptom severity and documents functional impairment

Tool	Description	How to Use	Interpretation
Daily Record of Severity of Problems (DRSP)	24-item daily rating scale; gold standard for research and clinical diagnosis	Patient rates each symptom daily from 1 (not at all) to 6 (extreme); marks menstruation days	PMDD: ≥30% increase in symptom scores in luteal vs. follicular phase; functional impairment items scored ≥4
Calendar of Premenstrual Experiences (COPE)	22-symptom daily diary	Daily symptom severity rating over 2+ cycles	Confirms cyclical pattern and identifies predominant symptoms
Premenstrual Symptoms Screening Tool (PSST)	Retrospective screening questionnaire; 19 items	Initial screening; not diagnostic but identifies candidates for prospective tracking	Positive screen: suggests need for prospective confirmation
Smartphone Apps	Various menstrual tracking apps with mood/symptom logging	Daily symptom entry; often includes cycle prediction	Convenient for patients; data can be reviewed at follow-up; validity varies by app

Practical Tip

Provide patients with a simple paper diary or recommend a specific app. Ask them to rate their top 3-5 symptoms daily on a 0-10 scale and mark menstruation days. Review the diary at follow-up to confirm: (1) symptoms worsen in the luteal phase, (2) symptoms resolve within a few days of menstruation, and (3) there is at least one symptom-free week.

Baseline Laboratory Investigations

While not required for diagnosis, baseline investigations are recommended to exclude common mimics and identify comorbidities. The extent of testing should be guided by clinical suspicion from history and examination.

Investigation	Purpose	What to Look For	Practical Points
Thyroid-Stimulating Hormone (TSH)	Exclude thyroid dysfunction	Elevated TSH (hypothyroidism); Suppressed TSH (hyperthyroidism)	Recommended for all patients; thyroid disease is common and easily missed
Complete Blood Count (CBC)	Exclude anemia	Low hemoglobin, low MCV (iron deficiency)	Especially important if heavy menstrual bleeding or fatigue is prominent
Ferritin	Assess iron stores	Ferritin <30 μg/L suggests iron deficiency (even with normal hemoglobin)	Iron deficiency without anemia can cause fatigue and cognitive symptoms
Fasting Glucose or HbA1c	Exclude diabetes	Fasting glucose ≥7.0 mmol/L; HbA1c ≥6.5%	Consider if obesity, family history, or symptoms suggest diabetes
Pregnancy Test	Exclude pregnancy	Positive β-hCG	Always consider in reproductive-age women with new or changed symptoms

Targeted Investigations by Clinical Suspicion

If Suspecting Thyroid Dysfunction

First-Line Tests

TSH: Most sensitive screening test; abnormal result directs further testing
Free T4: If TSH abnormal; confirms hypo- or hyperthyroidism

Second-Line Tests

Free T3: If hyperthyroidism suspected and Free T4 normal
Thyroid antibodies: Anti-TPO, anti-thyroglobulin if autoimmune thyroiditis suspected

If Suspecting Perimenopause

Clinical Assessment

Menstrual history: Cycle irregularity is the hallmark
Vasomotor symptoms: Hot flashes and night sweats
Diagnosis is usually clinical in women aged 45-55 with typical symptoms

Laboratory Tests (Limited Utility)

FSH: Elevated (>25 IU/L) but fluctuates widely in perimenopause; single value not diagnostic
Estradiol: Variable; not useful for diagnosis
Testing generally not recommended in typical perimenopause presentation in appropriate age group

If Suspecting Hyperprolactinemia

First-Line Tests

Prolactin level: Fasting, morning sample; avoid breast stimulation before test
Mild elevation (up to 100 μg/L): may be drug-induced or stress-related
Significant elevation (>100 μg/L): suggests prolactinoma

Second-Line Tests

MRI pituitary: If prolactin significantly elevated; to detect prolactinoma
Review medications: Antipsychotics, metoclopramide, and others elevate prolactin

If Suspecting Polycystic Ovary Syndrome (PCOS)

First-Line Tests

Testosterone (total and free): Mildly elevated in PCOS
LH:FSH ratio: Often elevated (>2:1) but not required for diagnosis
Pelvic ultrasound: Polycystic ovarian morphology (≥20 follicles per ovary or ovarian volume >10 mL)

Additional Considerations

17-hydroxyprogesterone: To exclude non-classic congenital adrenal hyperplasia
Fasting glucose, HbA1c: Metabolic screening
Lipid profile: Metabolic syndrome screening

If Suspecting Underlying Mood Disorder

Screening Tools

PHQ-9: Depression screening; score ≥10 suggests moderate depression
GAD-7: Anxiety screening; score ≥10 suggests moderate anxiety
MDQ: Mood Disorder Questionnaire for bipolar disorder screening

Key Considerations

Administer screening tools during follicular phase (symptom-free week) to assess baseline
Positive screening during symptom-free week suggests underlying disorder, not just PMS
Consider psychiatric referral if significant psychopathology identified

Imaging Studies

Imaging Modality	Indication	What It Detects	When to Order
Pelvic Ultrasound	Pelvic mass suspected; significant pelvic pain; menstrual irregularity	Ovarian cysts, fibroids, adenomyosis features, endometriomas	Not routine for PMS/PMDD; indicated if examination abnormal or pelvic pathology suspected
Breast Ultrasound/Mammography	Discrete breast mass; focal non-cyclical pain	Breast masses, cysts, calcifications	Not indicated for typical cyclical mastalgia; required if mass palpated or high-risk features
MRI Pituitary	Elevated prolactin level	Pituitary adenoma (prolactinoma)	If prolactin significantly elevated (>100 μg/L)
CT/MRI Brain	Atypical headaches; focal neurological signs	Intracranial pathology	Not routine; only if headaches have red flag features

Pre-Treatment Baseline Investigations

Before initiating specific treatments, certain baseline investigations may be required:

Planned Treatment	Recommended Baseline Tests	Rationale
SSRI Therapy	Generally none required; consider baseline sodium in elderly or those on diuretics	SSRIs can cause hyponatremia (SIADH), especially in older patients
Combined Oral Contraceptives	Blood pressure; assess cardiovascular and thrombotic risk factors	Contraindicated in certain conditions (migraine with aura, hypertension, thrombophilia)
GnRH Agonists	Baseline DEXA scan (bone density); lipid profile	Prolonged use causes bone loss and unfavorable lipid changes
Spironolactone	Baseline potassium, renal function	Risk of hyperkalemia; contraindicated in renal impairment
Danazol	Liver function tests; lipid profile	Hepatotoxicity and adverse lipid effects possible

Empiric Treatment Trials as Diagnostic Tools

Therapeutic Trial Approach

In some cases, response to treatment can support the diagnosis. This is particularly useful when:

Prospective symptom tracking is difficult to obtain
The clinical picture is highly suggestive of PMS/PMDD
Rapid relief is needed (e.g., severe symptoms affecting work or relationships)

Therapeutic Trial	Duration	Expected Response in PMS/PMDD	Interpretation
SSRI (luteal phase dosing)	1-2 menstrual cycles	Significant improvement in mood symptoms within 24-48 hours of starting in luteal phase	Rapid response supports PMDD diagnosis; lack of response may suggest misdiagnosis or need for continuous dosing
Combined oral contraceptive (continuous or extended cycle)	3 menstrual cycles	Reduction in symptoms, especially with continuous dosing that eliminates hormone-free interval	Response supports hormonal contribution; some women worsen on hormonal contraception
GnRH agonist (with add-back)	3 months	Complete resolution of symptoms (ovulation suppressed)	Confirms that symptoms are ovulation-dependent; helps predict response to surgical menopause if considered

Summary: Recommended Investigations by Clinical Scenario

Clinical Scenario	Recommended Investigations
Classic PMS presentation, no red flags	Prospective symptom diary × 2 cycles; TSH; consider CBC and ferritin
Suspected PMDD	Prospective symptom diary (DRSP) × 2 cycles; safety assessment; TSH; CBC
Symptoms persist throughout cycle	Prospective diary to document lack of symptom-free week; PHQ-9, GAD-7 (in follicular phase); TSH; consider psychiatric referral
New symptoms after age 40	TSH; FSH (if diagnosis unclear); CBC; consider perimenopausal evaluation
Significant fatigue with heavy bleeding	CBC; ferritin; TSH; consider pelvic ultrasound for fibroids
Breast tenderness with galactorrhea	Prolactin; TSH; pituitary MRI if prolactin elevated
Significant pelvic pain and dysmenorrhea	Pelvic examination; pelvic ultrasound; consider gynecology referral for endometriosis evaluation

7. Pattern Recognition and Clinical Decision-Making

Practical algorithms and decision pathways for premenstrual symptoms

Step 1: Is This Urgent?

Clinical Scenario	Urgency Level	Immediate Action
Suicidal ideation or self-harm thoughts	EMERGENT	Immediate safety assessment; consider psychiatric emergency referral; do not discharge if actively suicidal; initiate SSRI if appropriate
Severe functional impairment (unable to work, care for children, relationship crisis)	URGENT	Expedite diagnosis; consider empiric SSRI treatment while awaiting prospective confirmation; close follow-up within 1-2 weeks
New breast mass or unilateral focal breast pain	URGENT	Breast imaging; do not attribute to PMS without excluding pathology
Significant abdominal distension with pain	URGENT	Abdominal examination; consider imaging to exclude ovarian pathology or ascites
Typical PMS symptoms with moderate impact	ROUTINE	Provide prospective symptom diary; baseline investigations; lifestyle counseling; follow-up in 2-3 months
Mild premenstrual symptoms, minimal distress	ROUTINE	Reassurance; lifestyle advice; symptom tracking optional; return if symptoms worsen

Step 2: Initial Assessment Algorithm

First Visit Decision Tree:

Screen for red flags — Suicidal ideation? New mass? Atypical features? → Address urgently if present
Take focused history — Use “CYCLES” mnemonic; assess symptom pattern and impact
Ask the key question: “Is there a week during your cycle when you feel completely like yourself?”
- YES → Likely true PMS/PMDD → Proceed to Step 3
- NO → Consider premenstrual exacerbation or underlying condition → Screen for depression/anxiety; investigate accordingly
Perform targeted examination — Thyroid, breast, abdomen; mental status if mood symptoms prominent
Order baseline investigations — TSH, CBC, ferritin (minimum)
Provide prospective symptom diary — Essential for confirming diagnosis
Schedule follow-up — After 2 complete menstrual cycles with diary

Step 3: Classify by Severity

Mild Symptoms

Criteria: Symptoms noticed but no significant distress or functional impairment

Action: Reassurance; lifestyle modifications; no pharmacotherapy needed

Moderate (PMS)

Criteria: Symptoms cause distress; some impact on work, relationships, or daily activities

Action: Lifestyle modifications; consider supplements (calcium, vitamin B6); if insufficient, trial SSRI or hormonal therapy

Severe (PMDD)

Criteria: Marked affective symptoms; significant functional impairment; meets DSM-5 criteria

Action: First-line: SSRI (continuous or luteal phase); consider hormonal suppression if SSRI fails; psychiatric referral if complex

Step 4: Treatment Selection Algorithm

Algorithm A: Mild Premenstrual Symptoms

Intervention	Details	Expected Outcome
Lifestyle modifications	Regular aerobic exercise (30 minutes, 5 days/week); reduce caffeine, alcohol, salt; stress management; adequate sleep	Improvement in 1-3 cycles; may be sufficient as sole intervention
Dietary supplements	Calcium 1000-1200 mg/day; Vitamin B6 50-100 mg/day; Magnesium 200-400 mg/day	Modest benefit; low risk; can be used long-term
Reassurance and education	Validate symptoms; explain cyclical nature; provide written information	Reduces anxiety about symptoms; improves coping

Algorithm B: Moderate PMS

Step	Intervention	Duration/Assessment	If Inadequate Response
Step 1	Lifestyle modifications + supplements (calcium, vitamin B6)	2-3 cycles	Proceed to Step 2
Step 2	Add SSRI (luteal phase dosing) OR combined oral contraceptive (extended/continuous regimen)	2-3 cycles	Switch between options or proceed to Step 3
Step 3	Continuous SSRI dosing; consider drospirenone-containing oral contraceptive	3 cycles	Consider specialist referral; evaluate for PMDD

Algorithm C: Severe PMDD

Line	Intervention	Details	Response Assessment
First-line	SSRI	Sertraline 50-150 mg, fluoxetine 20 mg, or escitalopram 10-20 mg; can use luteal phase only (days 14-28) or continuous	Response often within 1-2 cycles; 60-70% respond
Second-line	Different SSRI or SNRI; or add/switch to hormonal therapy	Trial alternative SSRI if first fails; combined oral contraceptive (continuous) with drospirenone; or add to SSRI	Assess after 2-3 cycles
Third-line	GnRH agonist with add-back hormone therapy	Leuprolide or goserelin with low-dose estrogen/progestogen add-back to prevent bone loss	Near-complete symptom resolution expected; time-limited due to bone effects
Last resort	Surgical menopause (bilateral salpingo-oophorectomy)	Only after confirmed response to GnRH agonist; irreversible; requires hormone replacement therapy	Curative but significant implications; careful counseling required

Step 5: Symptom-Specific Interventions

Predominant Symptom	First-Line Approach	Second-Line Options
Mood symptoms (irritability, depression, anxiety)	SSRI (luteal or continuous); cognitive behavioral therapy	SNRI; hormonal suppression; anxiolytics short-term (not benzodiazepines long-term)
Breast tenderness (mastalgia)	Well-fitted supportive bra; reduce caffeine; evening primrose oil (gamma-linolenic acid)	Combined oral contraceptive; danazol (rarely, for severe refractory cases)
Bloating and fluid retention	Reduce salt intake; light exercise; drospirenone-containing oral contraceptive	Spironolactone 25-100 mg in luteal phase; thiazide diuretics (short-term)
Headaches (menstrual migraine)	NSAIDs started 2 days before expected menses; triptans for acute treatment	Perimenstrual frovatriptan prophylaxis; estrogen supplementation (if not contraindicated); magnesium
Food cravings and overeating	Regular meals; complex carbohydrates; protein with each meal; SSRIs help cravings	Cognitive behavioral therapy for binge eating if severe
Fatigue and low energy	Exclude anemia and thyroid disease; regular exercise; good sleep hygiene	SSRIs may help if mood-related; treat underlying cause if identified
Sleep disturbance	Sleep hygiene; limit caffeine; regular sleep schedule	Low-dose trazodone; melatonin; cognitive behavioral therapy for insomnia

Special Considerations

Population	Key Considerations	Recommended Approach
Adolescents	PMS/PMDD can begin at menarche; distinguish from adjustment issues; family involvement important	Lifestyle first; SSRIs safe if needed; involve parents in treatment decisions
Women trying to conceive	Many treatments contraindicated; SSRIs require discussion of risks/benefits in pregnancy	Lifestyle modifications; calcium/vitamin B6; low-dose SSRI if essential (discuss with patient); avoid hormonal suppression
Breastfeeding women	Limited medication options; symptoms may differ postpartum	Sertraline or paroxetine (low breast milk transfer); lifestyle modifications; reassess after weaning
Perimenopausal women	Symptoms often worsen; cycles irregular; transition to menopause eventually resolves symptoms	SSRIs effective; hormone therapy may help if also treating vasomotor symptoms; symptoms resolve after menopause
Women with contraindications to estrogen	Cannot use combined oral contraceptives (migraine with aura, thrombophilia, etc.)	SSRIs first-line; progestin-only methods may worsen symptoms; consider GnRH agonist with progestogen-only add-back for severe cases

“What Do I Do If…” Decision Reference

Clinical Situation	Immediate Action	Next Step
Patient reports suicidal thoughts premenstrually	Full safety assessment now; determine if thoughts are passive or active with plan	If high risk: psychiatric emergency referral. If lower risk: start SSRI immediately; close follow-up; safety planning; consider urgent psychiatry input
Prospective diary shows no symptom-free week	Reassess for underlying mood disorder or medical condition	Administer PHQ-9/GAD-7 during “best” week; treat underlying condition; not true PMS/PMDD
SSRI not tolerated (side effects)	Assess nature of side effects; consider dose reduction or slower titration	Trial different SSRI (side effect profiles vary); consider hormonal approach if SSRIs unsuitable
SSRI not effective after adequate trial	Confirm adequate dose and duration (at least 2 cycles at therapeutic dose)	Switch to different SSRI or SNRI; add or switch to hormonal therapy; reassess diagnosis
Patient worsens on combined oral contraceptive	Some women are sensitive to progestogens; hormone-free interval may trigger symptoms	Discontinue and reassess; trial continuous regimen to eliminate hormone-free week; or switch to SSRI-based approach
Patient requests surgical menopause	Discuss irreversibility; long-term implications; need for hormone therapy post-surgery	Require documented response to GnRH agonist trial first; multidisciplinary input; informed consent process
Symptoms return during hormone-free interval of oral contraceptive	Hormone withdrawal during pill-free week triggers symptoms	Switch to continuous or extended-cycle regimen (no hormone-free interval)
Patient wants “natural” treatment only	Respect preferences; discuss evidence for non-pharmacological approaches	Emphasize lifestyle (exercise, diet, stress management); calcium, vitamin B6, magnesium supplements; cognitive behavioral therapy; reassess if symptoms remain severe

Troubleshooting Refractory Premenstrual Symptoms

Ask These Questions When Symptoms Persist

Is the diagnosis correct? Review prospective diary — is there truly a symptom-free week? Could this be premenstrual exacerbation of another condition?
Was the treatment adequate? Sufficient dose? Adequate duration (at least 2-3 cycles)? Correct timing (luteal phase for intermittent dosing)?
Is adherence good? Patients may not take medication as prescribed, especially if side effects occur
Are there multiple overlapping causes? Consider comorbid conditions (thyroid, anemia, endometriosis) that may be contributing
Is there an underlying psychiatric disorder? Depression, anxiety, bipolar disorder, or PTSD may need specific treatment
Are lifestyle factors being addressed? Stress, sleep, exercise, caffeine, and alcohol can significantly impact symptoms
Should a specialist be involved? Consider referral to gynecology (for hormonal management), psychiatry (for complex mood symptoms), or a PMS specialist clinic if available

When to Refer

Referral Type	Indications
Psychiatry	Suicidal ideation; unclear diagnosis between PMDD and mood disorder; complex psychiatric comorbidity; bipolar disorder suspected; failed multiple treatment trials
Gynecology	Consideration of GnRH agonist therapy; surgical menopause consideration; coexisting gynecologic pathology (endometriosis, fibroids); contraceptive counseling for complex patients
Endocrinology	Complex thyroid disease; hyperprolactinemia requiring investigation; adrenal pathology suspected
Psychology/Counseling	Cognitive behavioral therapy for PMS; coping skills development; relationship counseling if symptoms causing significant interpersonal difficulties

8. Clinical Pearls and Pitfalls

Practical wisdom — learn from successes and avoid common mistakes

Must-Know Clinical Pearls

The symptom-free week is the diagnostic key: True PMS and PMDD require at least one week (typically follicular phase) when the patient feels like her normal self. Without this symptom-free interval, consider premenstrual exacerbation of an underlying condition.

SSRIs work differently in PMDD: Unlike major depression (which requires 4-6 weeks for response), SSRIs produce improvement within 24-48 hours in PMDD. This allows for intermittent luteal phase dosing, which is equally effective as continuous dosing for many patients.

Prospective tracking is essential: Retrospective recall is unreliable, and up to 50% of women who believe they have PMS do not demonstrate cyclicity on prospective tracking. Always provide a symptom diary and review it before confirming the diagnosis.

The hormones are normal — the brain response is abnormal: Women with PMDD do not have abnormal hormone levels. They have an abnormal central nervous system response to normal hormonal fluctuations. This explains why ovulation suppression works — it eliminates the fluctuations.

Suicidal ideation is common in PMDD: Up to 15% of women with PMDD experience suicidal thoughts. Always screen for safety, especially during the luteal phase when symptoms peak.

The hormone-free week can trigger symptoms: Women on combined oral contraceptives may experience PMS-like symptoms during the pill-free interval. Switching to a continuous regimen (skipping the placebo week) can resolve this.

Exercise is underrated as treatment: Regular aerobic exercise (30 minutes, 5 times per week) has evidence supporting its efficacy in PMS. It should be recommended to all patients as first-line therapy.

GnRH agonist response predicts surgical outcome: Before considering bilateral oophorectomy for refractory PMDD, a trial of GnRH agonist confirms that symptoms are ovulation-dependent. If symptoms resolve with GnRH agonist, surgical menopause will likely be curative.

Critical Pitfalls to Avoid

Diagnosing PMS without confirming cyclicity: Many women attribute chronic symptoms to their menstrual cycle. Without a prospective diary showing a symptom-free follicular phase, you may be missing an underlying mood disorder or medical condition.

Dismissing symptoms as “just hormonal”: PMS and PMDD are real conditions with neurobiological underpinnings. Dismissing symptoms invalidates the patient’s experience and delays effective treatment. Normal examination does not mean symptoms are not real.

Failing to screen for suicidal ideation: Suicidal thoughts are common in PMDD. Failing to ask about safety can have devastating consequences. Ask directly, especially during the luteal phase.

Checking hormone levels to “diagnose” PMS: There is no blood test that diagnoses PMS or PMDD. Hormone levels are normal in affected women. Testing estrogen or progesterone levels is unhelpful and may mislead both clinician and patient.

Giving up on SSRIs too quickly: Ensure adequate dose and duration (at least 2 cycles at therapeutic dose) before concluding failure. Also ensure correct timing if using luteal phase dosing. If one SSRI fails, another may work.

Forgetting to check TSH: Thyroid dysfunction mimics PMS beautifully and is very common in women. A simple TSH can identify a readily treatable cause. Check it in every patient.

Attributing new breast mass to “cyclical changes”: While cyclical bilateral breast tenderness is typical of PMS, any discrete mass or focal unilateral pain requires breast imaging. Do not assume all breast symptoms are hormonal.

Starting hormonal contraception without discussion of mood effects: Some women worsen on hormonal contraception. Counsel patients that mood symptoms may improve, stay the same, or worsen, and arrange follow-up to reassess.

Key Takeaways

Cyclicity is the diagnostic cornerstone: True PMS/PMDD requires symptoms limited to the luteal phase with a symptom-free follicular week. Without this pattern, consider premenstrual exacerbation of an underlying condition.
Prospective symptom tracking is mandatory: Retrospective recall is unreliable. Provide a daily symptom diary and review it after 2 complete cycles before confirming the diagnosis, especially for PMDD.
Severity determines treatment approach: Mild symptoms respond to lifestyle changes and supplements. Moderate PMS may need SSRIs or hormonal therapy. Severe PMDD requires pharmacotherapy, often SSRIs as first-line.
SSRIs work rapidly in PMDD: Response occurs within days, not weeks, allowing for effective luteal phase-only dosing in many patients. This is a unique feature distinguishing PMDD from major depression.
Normal physical examination is expected: PMS and PMDD are diagnoses based on history and symptom pattern. Investigations serve to exclude mimics (thyroid disease, anemia) rather than confirm the diagnosis.
Always screen for safety: Suicidal ideation affects up to 15% of women with PMDD. Ask about self-harm and suicidal thoughts directly, especially during the symptomatic luteal phase.
Multiple etiologies can coexist: A patient may have PMS and an underlying anxiety disorder, or PMS and thyroid disease. Address all contributing factors for optimal outcomes.
Hormonal suppression is an option for refractory cases: Combined oral contraceptives (continuous regimens), and GnRH agonists with add-back therapy can suppress ovulation and eliminate the hormonal fluctuations that trigger symptoms.
Consider the whole patient: Impact on relationships, work, and quality of life should guide treatment intensity. What is “tolerable” varies between patients.
Premenstrual symptoms will resolve with menopause: While perimenopause may worsen symptoms, true PMS/PMDD resolves after menopause when ovarian cycling ceases. This can be reassuring for patients.

Quick Reference Algorithm

Systematic Approach to Premenstrual Symptoms:

Screen for red flags: Suicidal ideation → immediate safety assessment. New mass → imaging. Symptoms throughout cycle → evaluate for underlying condition.
Confirm cyclicity: Ask about symptom-free week. Provide prospective symptom diary for 2 cycles.
Exclude mimics: Check TSH and CBC/ferritin at minimum. Consider pregnancy test. Physical examination to exclude organic pathology.
Classify severity: Mild (lifestyle advice), Moderate PMS (stepwise therapy), or Severe PMDD (SSRI first-line).
Initiate treatment: All patients — lifestyle modifications (exercise, diet, stress management). Add supplements (calcium, vitamin B6) for mild-moderate. Add SSRI (continuous or luteal phase) for moderate-severe. Consider hormonal therapy if SSRI inadequate or contraindicated.
Reassess after 2-3 cycles: Review symptom diary. Assess treatment response. Adjust therapy as needed.
Escalate if refractory: Confirm diagnosis. Optimize current treatment. Consider specialist referral (gynecology, psychiatry). For severe refractory PMDD: GnRH agonist trial, with surgical menopause as last resort.